Princeton Satellite Systems (United States)

Recent papers from Princeton Satellite Systems (United States)

1. An Arduino-Based Butane Leak Detection System With Automated Ventilation and Internet of Things (IoT) Mobile ApplicationCureus · 2026
2. Risk-Based Software Test Prioritization via Machine-Learning Defect Prediction: Label-Feature Circularity, Clean Baselines, and an Honest Empirical Study on Five Open-Source Repositories2026
3. Risk-Based Software Test Prioritization via Machine-Learning Defect Prediction: Label-Feature Circularity, Clean Baselines, and an Honest Empirical Study on Five Open-Source Repositories2026
4. Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cellsCellular Oncology · 2026
5. 1669-P: Effect of Semaglutide for Weight Management on Blood Pressure in Adults with Uncontrolled Hypertension and Overweight/Obesity: A Post Hoc Analysis from the STEP and OASIS ProgramsDiabetes · 2026
6. 2838-LB: Cardiometabolic Effects of Semaglutide in OASIS 4 Participants by BMI ClassDiabetes · 2026
7. 2834-LB: Cardiometabolic Outcomes in Adults with T2D Treated with 1 mg Semaglutide Who Titrate to 2 mg Semaglutide vs. Switch to TirzepatideDiabetes · 2026
8. 2350-P: Unmet Need in Post-Stroke Antidiabetic Treatment Patterns among Individuals Newly Diagnosed with Type 2 Diabetes (T2D) during Ischemic Stroke HospitalizationDiabetes · 2026
9. 2836-LB: HbA1c and Weight Outcomes among Adults with Type 2 Diabetes on 25 mg Oral Semaglutide Previously Treated with Metformin Only: A Post hoc Analysis from PIONEER PLUSDiabetes · 2026
10. 2843-LB: HbA1c and Weight Outcomes for Individuals with T2D Persistent on 25mg Oral Semaglutide: A PIONEER PLUS Post-Hoc AnalysisDiabetes · 2026
11. 1708-P: Comparing Major Adverse Kidney Events (MAKE) among New Users of Oral Semaglutide (SEMA) vs. Select Oral Antidiabetic Medications (ADMs) among U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)Diabetes · 2026
12. C71-27 Overexpression of the Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Enhances Extracellular Matrix Remodeling and Inflammatory Responses in Lung FibroblastsAmerican Journal of Respiratory and Critical Care Medicine · 2026
13. Abstract 648: PP2A reactivation upregulates FGA gene in neuroblastoma.Cancer Research · 2026
14. Abstract B023: Targeting therapy induced senescence with small molecule Protein Phosphatase 2A (PP2A) activators to prevent glioblastoma relapse after first line treatmentCancer Research · 2026
15. Abstract B059: A small molecule activator of the tumor suppressor phosphatase PP2A overcomes leptomeningeal dissemination in group 3 medulloblastomaCancer Research · 2026
16. The Natural History of Insomnia: Sleep Opportunity Extension Following a Poor Night of Sleep Is Not Related to the Transition From Acute to Chronic InsomniaJournal of Sleep Research · 2026
17. PP2A activation targets MYCN in neuroblastomaCell Death and Disease · 2026
18. Embedding Geriatric Oncology in a Community Practice of an Academic Health System: Implementation, Outcomes, and End-of-Life ImpactJCO Oncology Practice · 2026
19. Discovering Polyphosphate and Polyhydroxyalkanoate-Accumulating Organisms Across Ecosystems: Phenotype-Targeted Genotyping via FACS-SequencingEnvironmental Science & Technology · 2025
20. Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsCancer Research Communications · 2025